Company Active LTD

Company profile

Aglaris Limited

Aglaris

Aglaris Limited is a UK company with status active founded in 2014.

CRN
09111674
Founded
2014
Age
11

Overview

Legal name
AGLARIS LIMITED
Region
Unknown
Registered address
167-169 GREAT PORTLAND STREET GREAT PORTLAND STREET
5TH FLOOR
LONDON
ENGLAND
W1W 5PF
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

8 events
30 Oct
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

16 Oct
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

19 Oct
2024

Resolution

Resolution

RESOLUTIONS | Transaction WURERzI2QzBhZGlxemtjeA | Paper/PDF filed

Published 20 Oct 2024 06:17

18 Oct
2024

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQ0MDA0NTM5MmFkaXF6a2N4

Published 18 Oct 2024 08:50

10 Oct
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQzOTA2MjQ5NWFkaXF6a2N4

Published 10 Oct 2024 02:11

02 Jul
2014

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2018
Funded years
2018, 2020
Age at first award
3 years

Projects

2020 Collaborative R&D Lead participant

Development of transduction process in cell culture platform

13 Jul 2020 to 13 Jul 2021

Awarded
£724,476
Total cost £982,869

Development of transduction process in cell culture platform

2018 EU-Funded Lead participant

Thermoresponsive Microcarriers for Mesenchymal Stem Cells Cultures

1 Oct 2018 to 31 May 2021

Awarded
£250,617
Total cost £417,696

Awaiting Public Project Summary

2018 Collaborative R&D Lead participant

Improving T-Cell manufacture through automation - scaling out, reducing costs and increasing quality to meet the emerging demand for patient-tailored cancer therapies.

1 Jul 2018 to 30 Sep 2019

Awarded
£338,053
Total cost £482,932

"**Objective:** Improve scalability, quality, costs, flexibility and efficiency of T cell manufacturing by developing and integrating novel processes and manufacturing technologies. **Need or Challenges**: While T cells have been shown to produce game-changing results by curing previously untreatable cancers in numerous clinical trials, the T-cell manufac...

Product types

Collaborative R&D EU-Funded